Acquired resistance to vemurafenib associated with reactivation of MAPK signaling as observed by elevated ERK1/2 phosphorylation levels in progressive lesions and the appearance of secondary NRAS ( Q61 ) mutations or MEK1 ( Q56P ) or MEK1(E203K ) mutations .